Cited by 203Monoclonal and Polyclonal Antibodies ResearchProtein Interaction Studies and Fluorescence AnalysisT-cell and B-cell Immunology

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

Open access
Abdiche, Yasmina Noubia, Yeung, Yik Andy, Chaparro-Riggers, Javier, Barman, Ishita, Strop, Pavel, Chin, Sherman Michael, Pham, Amber, Bolton, Gary +4 more·2015·mAbs

Abstract

The neonatal Fc receptor (FcRn) is expressed by cells of epithelial, endothelial and myeloid lineages and performs multiple roles in adaptive immunity. Characterizing the FcRn/IgG interaction is fundamental to designing therapeutic antibodies because IgGs with moderately increased binding affinities for FcRn exhibit superior serum half-lives and efficacy. It has been hypothesized that 2 FcRn molecules bind an IgG homodimer with disparate affinities, yet their affinity constants are inconsistent across the literature. Using surface plasmon resonance biosensor assays that eliminated confounding experimental artifacts, we present data supporting an alternate hypothesis: 2 FcRn molecules saturate an IgG homodimer with identical affinities at independent sites, consistent with the symmetrical arrangement of the FcRn/Fc complex observed in the crystal structure published by Burmeister et al. in 1994. We find that human FcRn binds human IgG1 with an equilibrium dissociation constant (KD) of 760 ± 60 nM (N = 14) at 25°C and pH 5.8, and shows less than 25% variation across the other human subtypes. Human IgG1 binds cynomolgus monkey FcRn with a 2-fold higher affinity than human FcRn, and binds both mouse and rat FcRn with a 10-fold higher affinity than human FcRn. FcRn/IgG interactions from multiple species show less than a 2-fold weaker affinity at 37°C than at 25°C and appear independent of an IgG's variable region. Our in vivo data in mouse and rat models demonstrate that both affinity and avidity influence an IgG's serum half-life, which should be considered when choosing animals, especially transgenic systems, as surrogates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2015.1008353

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mouse and rat models differ from humans in key features including levels of FcRn expression, immunological function, and placental anatomy.

    “However, they differ from humans in many key features including levels of FcRn expression (132), immunological function (133), and placental anatomy (77).”

    From Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy (2017) · cites this paper as [132]

    The citation to this paper is attached to FcRn expression levels, not immunological function or placental anatomy. In the Results section (“Longer IgG serum half-life”), the paper says some animal models—especially transgenic ones—may express non-native FcRn levels. It does not establish that mouse and rat models generally have different FcRn expression levels from humans; no page number is available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

  • Reduced elimination of IgG antibodies by engineering the variable region

    Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · cited 1× · see citing works

    “hIgG1 25 737 (82) 16 332 (87) 12 72 (12) 17 68 (7) 14 hIgG1 37 998 (174) 6 372 (17) 4 164 (23) 8 135 (29) 8 hIgG2 25 540 (86) 10 250 (85) 5 63 (10) 8 53 (15) 8 hIgG2 37 768 (66) 6 333 (7) 4 147 (7) 4 93 (3) 4 hIgG3 25 585 (60) 5 188, 213 2 230 (34) 3 313 (109) 3 hIgG3 37 898 (64) 4 387 (22) 3 353, 328 2 357, 366 2 hIg…”

Flagged first, then by citations

Research works printed but not linked: 39

  1. [1]Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715- 25; PMID:17703228; http://dx.doi.org/ 10.1038/nri2155 17703228 · DOI · Paper page
  2. [2]Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2013; doi: 10.3109/07388551.2013.834293; PMID:24156398 24156398 PMC4876602 · DOI
  3. [3]Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182: 7663- 71; PMID:19494290; http://dx.doi.org/ 10.4049/jimmunol.0804182 19494290 · DOI
  4. [4]Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372: 379- 83; PMID:7969498; http://dx.doi.org/ 10.1038/372379a0 7969498 · DOI
  5. [5]Popov S, Hubbard JG, Kim J, Ober B, Ghetie V, Ward ES. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol Immunol 1996; 33: 521- 30; PMID:8700168; http://dx.doi.org/ 10.1016/0161-5890(96)00004-1 8700168 · DOI
  6. [6]Schuck P, Radu CG, Ward ES. Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1. Mol Immunol 1999; 36: 1117- 25; PMID:10698313; http://dx.doi.org/ 10.1016/S0161-5890(99)00093-0 10698313 · DOI
  7. [7]Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol 1993; 230: 1077- 83; PMID:8478919; http://dx.doi.org/ 10.1006/jmbi.1993.1220 8478919 · DOI
  8. [8]Sánchez LM, Penny DM, Bjorkman PJ. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry 1999; 38: 9471- 76; PMID:10413524; http://dx.doi.org/ 10.1021/bi9907330 10413524 · DOI
  9. [9]West AP Jr, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 2000; 39: 9698- 08; PMID:10933786; http://dx.doi.org/ 10.1021/bi000749m 10933786 · DOI
  10. [10]Raghavan M, Wang Y, Bjorkman PJ. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci USA 1995; 92: 11200- 204; PMID:7479965; http://dx.doi.org/ 10.1073/pnas.92.24.11200 7479965 PMC40599 · DOI
  11. [11]Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, Dall'Acqua WF. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem 2014; 289: 7812- 24; PMID:24469444; http://dx.doi.org/ 10.1074/jbc.M113.537563 24469444 PMC3953293 · DOI · Paper page
  12. [12]Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 1999; 38: 12639- 47; PMID:10504233; http://dx.doi.org/ 10.1021/bi9913505 10504233 · DOI
  13. [13]Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004; 101: 9763- 68; PMID:15210944; http://dx.doi.org/ 10.1073/pnas.0403235101 15210944 PMC470748 · DOI
  14. [14]Kamei DT, Lao BJ, Ricci MS, Deshpande R, Xu H, Tidor B, Lauffenburger DA. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol Bioeng 2005; 92: 748- 60; PMID:16136591; http://dx.doi.org/ 10.1002/bit.20624 16136591 · DOI
  15. [15]Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43: 1462- 73; PMID:16139891; http://dx.doi.org/ 10.1016/j.molimm.2005.07.032 16139891 · DOI
  16. [16]Kacskovics I, Kis Z, Mayer B, West AP Jr, Tiangco NE, Tilahun M, Cervenak L, Bjorkman PJ, Goldsby RA, Szenci O, et al. FcRn mediates elongated serum half-life of human IgG in cattle. Int Immunol 2006; 18: 525- 36; PMID:16481343; http://dx.doi.org/ 10.1093/intimm/dxh393 16481343 · DOI
  17. [17]Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35: 86- 94; PMID:17050651; http://dx.doi.org/ 10.1124/dmd.106.011734 17050651 · DOI
  18. [18]Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285: 4826- 36; PMID:20018855; http://dx.doi.org/ 10.1074/jbc.M109.081828 20018855 PMC2836088 · DOI
  19. [19]Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38: 600- 05; PMID:20071453; http://dx.doi.org/ 10.1124/dmd.109.031310 20071453 · DOI
  20. [20]Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184: 1968- 76; PMID:20083659; http://dx.doi.org/ 10.4049/jimmunol.0903296 20083659 · DOI
  21. [21]Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods 2012; 375: 20- 9; PMID:21939661; http://dx.doi.org/ 10.1016/j.jim.2011.09.002 21939661 · DOI
  22. [22]Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39: 1469- 77; PMID:21610128; http://dx.doi.org/ 10.1124/dmd.111.039453 21610128 · DOI
  23. [23]Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem 2012; 287: 22927- 37; PMID:22570488; http://dx.doi.org/ 10.1074/jbc.M112.355131 22570488 PMC3391105 · DOI
  24. [24]Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, et al Characterization and screening of IgG binding to the neonatal Fc receptor. mAbs 2014; 6: 928- 42; PMID:24802048; http://dx.doi.org/ 10.4161/mabs.28744 24802048 PMC4171027 · DOI
  25. [25]Myszka DG. Improving biosensor analysis. J Mol Recognit 1999; 12: 279- 84; PMID:10556875; http://dx.doi.org/ 10.1002/(SICI)1099-1352(199909/10)12:5%3c279::AID-JMR473%3e3.0.CO;2-3 10556875 · DOI · Paper page
  26. [26]Jakoi ER, Cambier J, Saslow S. Transepithelial transport of maternal antibody: purification of IgG receptor from newborn rat intestine. J Immunol 1985; 135: 3360- 64; PMID:2931482 2931482
  27. [27]Hobbs SM, Jackson LE, Peppard JV. Binding of subclasses of rat immunoglobulin G to detergent-isolated Fc receptor from neonatal rat intestine. J Biol Chem 1987; 262: 8041- 46; PMID:3597360 3597360
  28. [28]Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13: 1551- 59; PMID:11717196; http://dx.doi.org/ 10.1093/intimm/13.12.1551 11717196 · DOI
  29. [29]Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420: 204- 19; PMID:22543237; http://dx.doi.org/ 10.1016/j.jmb.2012.04.020 22543237 · DOI
  30. [30]Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276: 6591- 604; PMID:11096108; http://dx.doi.org/ 10.1074/jbc.M009483200 11096108 · DOI
  31. [31]Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA. Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Protein Sci 2003; 12: 1960- 70; PMID:12930995; http://dx.doi.org/ 10.1110/ps.03133903 12930995 PMC2323993 · DOI
  32. [32]Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor binding and monocyte triggering activities. Eur J Immunol 1999; 29: 2613- 24; PMID:10458776; http://dx.doi.org/ 10.1002/(SICI)1521-4141(199908)29:08%3c2613::AID-IMMU2613%3e3.0.CO;2-J 10458776 · DOI
  33. [33]Abdiche YN, Lindquist KC, Pinkerton A, Pons J, Rajpal A. Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis. Anal Biochem 2011; 411: 139- 51; PMID:21168382; http://dx.doi.org/ 10.1016/j.ab.2010.12.020 21168382 · DOI
  34. [34]Drake AW, Tang ML, Papalia GA, Landes G, Haak-Frendscho M, Klakamp SL. Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. Anal Biochem 2012; 429: 58- 69; PMID:22766435; http://dx.doi.org/ 10.1016/j.ab.2012.06.024 22766435 · DOI
  35. [35]Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 2010; 602: 93- 104; PMID:20012394; http://dx.doi.org/ 10.1007/978-1-60761-058-8_6 20012394 · DOI
  36. [37]Tesar DB, Tiangco NE, Bjorkman PJ. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 2006; 7: 1127- 2; PMID:17004319; http://dx.doi.org/ 10.1111/j.1600-0854.2006.00457.x 17004319 PMC1618808 · DOI
  37. [38]Bee C, Abdiche YN, Pons J, Rajpal A. Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum. PLoS One 2013; 8(11): e80501; PMID:24223227; http://dx.doi.org/ 10.1371/journal.pone.0080501 24223227 PMC3819287 · DOI
  38. [39]Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG. See comment in PubMed Commons belowExploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 2006; 358: 281- 88; PMID:16962556; http://dx.doi.org/ 10.1016/j.ab.2006.08.005 16962556 · DOI
  39. [40]Gastinel LN, Simister NE, Bjorkman PJ. Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. Proc Natl Acad Sci USA 1992; 89: 638- 42; PMID:1530991; http://dx.doi.org/ 10.1073/pnas.89.2.638 1530991 PMC48294 · DOI

Cited by

Sorted by citations

Authors
Abdiche, Y. N., Yeung, Y. A., Chaparro-Riggers, J., Barman, I., Strop, P., Chin, S. M., Pham, A., Bolton, G., McDonough, D., Lindquist, K., Pons, J., & Rajpal, A.
Affiliations
Pfizer (United States) (US)
Corresponding author
Abdiche, Yasmina Noubia
Venue
mAbs
Published
2015-02-06
Volume
7
Issue
2
Pages
331-343
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W1929182612
Cited by
203
References
1
Citations by year
2026: 23 · 2025: 23 · 2024: 18 · 2023: 11 · 2022: 25 · 2021: 15 · 2020: 19 · 2019: 18 · 2018: 17 · 2017: 13 · 2016: 13 · 2015: 5
FWCI
12.97
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • mAbs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
neonatal Fc receptor, IgG1, Macaca fascicularis, serum half-life, avidity, therapeutic antibodies, transgenic animal models, antibody pharmacokinetics
MeSH terms
Animals, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Macaca fascicularis, Receptors, Fc, Species Specificity, Histocompatibility Antigens Class I, Surface Plasmon Resonance, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review